Arizona State Retirement System Sells 507 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Arizona State Retirement System lessened its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 2.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,481 shares of the life sciences company’s stock after selling 507 shares during the quarter. Arizona State Retirement System’s holdings in Integra LifeSciences were worth $892,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ellsworth Advisors LLC increased its position in Integra LifeSciences by 4.0% during the 4th quarter. Ellsworth Advisors LLC now owns 106,612 shares of the life sciences company’s stock valued at $4,643,000 after purchasing an additional 4,112 shares during the period. Pacer Advisors Inc. lifted its stake in Integra LifeSciences by 71.9% during the 4th quarter. Pacer Advisors Inc. now owns 10,223 shares of the life sciences company’s stock valued at $445,000 after acquiring an additional 4,276 shares during the period. Raymond James & Associates lifted its stake in shares of Integra LifeSciences by 1.4% in the 4th quarter. Raymond James & Associates now owns 207,228 shares of the life sciences company’s stock valued at $9,025,000 after purchasing an additional 2,903 shares during the period. Empirical Asset Management LLC acquired a new position in shares of Integra LifeSciences in the 4th quarter valued at $212,000. Finally, Cascade Investment Advisors Inc. lifted its stake in shares of Integra LifeSciences by 6.3% in the 4th quarter. Cascade Investment Advisors Inc. now owns 26,775 shares of the life sciences company’s stock valued at $1,166,000 after purchasing an additional 1,590 shares during the period. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock opened at $31.82 on Wednesday. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $2.50 billion, a P/E ratio of 38.34, a P/E/G ratio of 0.99 and a beta of 1.12. The firm’s 50 day moving average is $37.51 and its two-hundred day moving average is $39.24. Integra LifeSciences Holdings Co. has a 52 week low of $31.57 and a 52 week high of $59.30.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The business had revenue of $397.00 million for the quarter, compared to analysts’ expectations of $399.30 million. During the same quarter last year, the business posted $0.94 earnings per share. The business’s revenue was down .3% on a year-over-year basis. Research analysts forecast that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. StockNews.com lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. JMP Securities reduced their price target on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research report on Thursday, February 29th. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target on the stock in a research report on Wednesday, April 3rd. Finally, Truist Financial reduced their target price on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a report on Friday, March 1st. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and an average price target of $44.89.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.